New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
09:45 EDTABT, ABT, THOR, THOR, TFX, TFX, SYK, SYK, STJ, STJ, NUVA, NUVA, MDT, MDT, HTWR, HTWR, HSP, HSP, EW, EW, COV, COV, CFN, CFN, BDX, BDX, BSX, BSX, BCR, BCR, BAX, BAX, ZMH, ZMHBarclays' U.S. medical suppplies & devices analysts hold a conference call
U.S. Medical Supplies & Devices Research Team discuss key potential catalysts and top ideas for 2013 on an Analyst/Industry conference call. Relevant covered companies ABT, BAX, BCR, BSX, BDX, CFN, COV, EW, HSP, HTWR, MDT, NUVA, STJ, SYK, TFX, THOR and ZMH will be discussed on the Analyst/Industry conference call to be held January 17 at 10 am.
News For ABT;BAX;BCR;BSX;BDX;CFN;COV;EW;HSP;HTWR;MDT;NUVA;STJ;SYK;TFX;THOR;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 14, 2015
09:41 EDTBSX, ABT, MDT, STJLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:45 EDTZMHZimmer has a conference call hosted by JPMorgan
Subscribe for More Information
07:15 EDTTFXTeleflex to host investor and analyst meeting
Subscribe for More Information
May 13, 2015
19:17 EDTHSPHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
13:43 EDTHSPHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
10:40 EDTBAXBaxter to host two day investor meeting
Two day Investor meeting to be held in New York May 18-19.
08:08 EDTSTJSt. Jude Medical receives CE Mark approval of Ellipse expanded labeling
Subscribe for More Information
08:07 EDTBDXBecton Dickinson receives FDA clearance for insulin infusion set
Subscribe for More Information
07:31 EDTSYK, BSX, STJHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
11:43 EDTSYKStryker backs FY15 organic revenue growth of 5%-6%
Subscribe for More Information
10:02 EDTMDTMedtronic receives FDA approval and CE Mark for Advance ST cryoballoon
Subscribe for More Information
10:01 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:02 EDTBAXBaxter expects to establish BioScience business as separate business by mid-year
Subscribe for More Information
09:01 EDTBAXBaxter to acquire Oncaspar product portfolio from Sigma-Tau for $900M
Subscribe for More Information
07:35 EDTSTJBofA/Merrill to hold a conference
Subscribe for More Information
07:06 EDTBAXKamada sees FY15 revenue $70M-$73M, consensus $78.69M
Kamada (KMDA) sees revenue from its Distributed Product Segment projected to be between $26 million and $28 million and revenue from its Proprietary Products Segment projected to be between $45 million and $47 million. The company notes that revenue projections for 2015 take into account an expected negative foreign exchange impact of approximately $2.0 million in relation to product sales in Israel and Russia, and presume that U.S. revenue from the agreement with Baxter (BAX) remains on track.
06:48 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Edwards Lifesciences to Overweight following the 15% selloff since mid-March. The firm says its confidence in the conversion of the surgical valve replacement market to transcatheter replacement increased significantly at this year's ACC. It adds that its recent field work indicates the TAVR market has accelerated post-ACC. JPMorgan raised its price target for shares to $155 from $147.
06:35 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
05:23 EDTBSXNevro announces filing of petitions for inter partes review by Boston Scientific
Subscribe for More Information
May 11, 2015
10:30 EDTABTAbbott names Brian Yoor as SVP, Finance and CFO
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use